| Patient number |
Age |
Diabetes mellitus type |
Duration period of DM (years) |
Principal therapy DM |
Average compensation according to HbA1c |
Type of diabetic retinopathy |
Type of diabetic macular edema |
Previous therapy of DME |
Concomitant diseases |
| 1 |
68 |
2 |
6 |
PAD |
5.50% |
Nonproliferative |
Diffuse |
3x focal laser of the macula |
Decompensated arterial hypertension |
| 2 |
73 |
2 |
20 |
INZ |
8% |
Risk nonproliferative |
Diffusion ischemic |
PRF, 4x focal laser |
Arterial hypertension |
| 3 |
68 |
2 |
18 |
INZ |
7.40% |
Nonproliferative |
Diffuse |
Incomplete GRID OPL |
Arterial hypertension, hyperlipidaemia |
| 4 |
77 |
2 |
19 |
INZ |
8.20% |
Nonproliferative |
Diffuse |
Incomplete GRID OPL |
Arterial hypertension, hyperlipidaemia, stroke |
| 5 |
56 |
2 |
10 |
PAD |
9.40% |
Nonproliferative |
Focal |
3x focal laser of the macula |
Asthma |
| 6 |
82 |
2 |
25 |
INZ |
6.50% |
Risk nonproliferative |
Diffuse |
2x focal laser of the macula, incomplete PRF |
Arterial hypertension, hyperlipidaemia |
| 7 |
69 |
1 |
30 |
INZ |
10% |
Proliferative |
Diffuse |
PRF left |
Arterial hypertension, ischemic heart disease, peripheral arterial disease, right lower limb amputation |
| 8 |
57 |
2 |
7 |
PAD |
6.80% |
Nonproliferative |
Diffuse |
3x focal laser of the macula, 4x study medication (Ozurdex/placebo) |
0 |
| 9 |
56 |
2 |
10 |
PAD+INZ |
9.30% |
Proliferative |
Focal |
PRF |
Arterial hypertension |
| 10 |
70 |
2 |
24 |
PAD |
5.60% |
Nonproliferative |
Focal |
1x focal laser of the macula |
Ischemic heart disease |
| 11 |
45 |
1 |
30 |
INZ |
5.60% |
Risk nonproliferative |
Diffuse |
2x focal laser of the macula, incomplete PRF |
Arterial hypertension, frequent hypoglycaemias |
| 12 |
75 |
2 |
19 |
INZ |
6.20% |
Nonproliferative |
Diffuse |
2x focal laser of the macula |
Arterial hypertension, hyperlipoproteinaemia, operation of valvular defect |
| 13 |
65 |
2 |
25 |
INZ |
8.50% |
Nonproliferative |
Focal |
2x focal laser of the macula |
Arterial hypertension, heavy obesity,
diabetic foot |
